Cibus narrows Q1 loss, extends cash runway as it pivots to commercial execution
Operating expenses drop significantly year-on-year, while US rice launch slips to 2029 due to regulatory timelines.
Cibus has reported a narrower net loss for the first quarter of 2026, recording a deficit of $21.2 million compared to $49.4 million in the same period last year. The improvement was driven by a near $8 million reduction in operating expenses, stemming from cost-cutting initiatives and the absence of litigation costs that weighed on the prior year’s results. The company also secured approximately $37 million in gross proceeds through two public offerings in January and March, extending its cash runway into late Q1 2027.
The firm marked a strategic shift from foundational development in 2025 to commercial execution, highlighted by the delivery of gene-edited, herbicide-tolerant rice material to partner Interoc. This milestone supports a planned 2027 commercial launch in Latin America, with initial market entry targeted for Ecuador and Colombia. The transfer follows an import permit received by Interoc in March and a non-binding letter of intent signed in January, establishing a framework for the commercialisation of co-developed traits across key regional markets.
While progress accelerates in Latin America, the US launch for rice herbicide tolerance has been delayed from 2028 to 2029. The revised timeline reflects regulatory registration timelines for chemistry partner Albaugh, whose clethodim herbicide registration is a gating item for the US market. Management noted that the US represents a smaller acreage opportunity compared to Latin America, which remains the primary thrust for near-term revenue generation.
In its Sustainable Ingredients division, Cibus is advancing its biofragrance program with a CPG partner, targeting commercial scale production during 2026. The company expects additional scale-up orders for its initial biofragrances in the second half of the year. This segment is viewed as a near-term revenue bridge, with potential annual royalties estimated between $20 million and $40 million once fully commercialised, leveraging the same yeast platform used for crop traits.
Financially, research and development expenses fell to $8.7 million from $11.8 million, while selling, general and administrative expenses decreased to $5.1 million from $9.9 million. Cash and cash equivalents stood at $30.3 million as of March 31, 2026. The company remains on target to deliver annual net cash usage of approximately $30 million or less in 2026, with burn rates expected to decrease further in the second half of the year as restructuring effects take hold.
